The relevance of mitochondrial DNA variants fluctuation during reprogramming and neuronal differentiation of human iPSCs

The generation of inducible pluripotent stem cells (iPSCs) is a revolutionary technique allowing production of pluripotent patient-specific cell lines used for disease modeling, drug screening, and cell therapy. Integrity of nuclear DNA (nDNA) is mandatory to allow iPSCs utilization, while quality control of mitochondrial DNA (mtDNA) is rarely included in the iPSCs validation process. In this study, we performed mtDNA deep sequencing during the transition from parental fibroblasts to reprogrammed iPSC and to differentiated neuronal precursor cells (NPCs) obtained from controls and patients affected by mitochondrial disorders. At each step, mtDNA variants, including those potentially pathogenic, fluctuate between emerging and disappearing, and some having functional implications. We strongly recommend including mtDNA analysis as an unavoidable assay to obtain fully certified usable iPSCs and NPCs. [Display omitted] •mtDNA deep sequencing is mandatory in quality control of iPSCs•mtDNA variants fluctuate at each step from fibroblasts/PBMC, to iPSCs and NPCs•mtDNA variants greatly affect iPSC phenotype, reflecting their healthiness•Results could be misinterpreted if mtDNA variants presence has not been assessed Tiranti and colleagues observed that quality control of iPSCs rarely includes the analysis of mitochondrial DNA (mtDNA), a small circular molecule present in the mitochondria. However, mtDNA variants greatly affect the final phenotype of iPSCs. They highlighted that iPSC-derived neuronal precursors could also present mtDNA variants and underlined the paramount importance of screening mtDNA.